Loading...
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demon...
Na minha lista:
| Udgivet i: | Allergy Asthma Clin Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6448265/ https://ncbi.nlm.nih.gov/pubmed/30988677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0337-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|